Compare GSK plc (GSK) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| GSK | VWO | |
|---|---|---|
Market Cap | $91.88B | $168.50B |
Volume | 7,730,529 | 9,650,999 |
Sector | Health | — |
52-Week High | $61.18 | $61.44 |
52-Week Low | $43.24 | $52.42 |
Typical Hold Time | 93 Days | 135 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
VWO trades at $59.10, down 1.25% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent institutional buying by Allianz and Alamar Capital contrasts with technical weakness.
The emerging markets ETF offers diversification but faces headwinds from China's property and consumer weakness. Technical indicators suggest caution near-term, though institutional accumulation and AI infrastructure demand provide potential catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
